Jiksak Bioengineering Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
2ndary - Private
- Investors
-
8
Jiksak Bioengineering General Information
Description
Developer of neuron-targeted drug delivery technologies designed for neurodegenerative disease treatment. The company's platform delivers therapeutic candidates directly into neurons through natural biological pathways and supports nerve repair and neurological research, enabling biotechnology and pharmaceutical markets to develop treatments for ALS and other neurological disorders.
Contact Information
Website
www.jiksak.co.jpCorporate Office
- Cybernics Medical Innovation Base-A Room 322
- 3-25-16 Tonomachi, Kawasaki-ku
- Kawasaki, Kanagawa 210-0821
- Japan
Corporate Office
- Cybernics Medical Innovation Base-A Room 322
- 3-25-16 Tonomachi, Kawasaki-ku
- Kawasaki, Kanagawa 210-0821
- Japan
Jiksak Bioengineering Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Secondary Transaction - Private | 18-Mar-2026 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B) | 29-Aug-2022 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 01-Oct-2021 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series B) | 01-Feb-2021 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 22-Feb-2018 | Completed | Startup | |||
| 3. Accelerator/Incubator | 01-Feb-2018 | Completed | Startup | |||
| 2. Angel (individual) | 21-Apr-2017 | $136K | $136K | Completed | Startup | |
| 1. Accelerator/Incubator | 01-Feb-2017 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Jiksak Bioengineering Patents
Jiksak Bioengineering Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026086103-A | In vitro pain model and method for measuring pain using same | Pending | 14-Nov-2024 | ||
| WO-2026079407-A1 | Targeting agent | Pending | 08-Oct-2024 | ||
| WO-2025089341-A1 | Anti-synaptic vesicle glycoprotein 2c antibody | Inactive | 25-Oct-2023 | ||
| WO-2025089342-A1 | Anti-synaptic vesicle glycoprotein 2c antibody | Inactive | 25-Oct-2023 | ||
| WO-2025089343-A1 | Anti-synaptic vesicle glycoprotein 2c antibody | Inactive | 25-Oct-2023 |
Jiksak Bioengineering Signals
Jiksak Bioengineering Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CEJ Capital | Corporate Venture Capital | Minority | ||
| Cyberdyne | Corporation | Minority | ||
| SBI Investment | Venture Capital | Minority | ||
| Zeon (Tokyo) | Corporation | Minority | ||
| JAPAN CONVENTION SERVICES | Accelerator/Incubator |
Jiksak Bioengineering FAQs
-
When was Jiksak Bioengineering founded?
Jiksak Bioengineering was founded in 2017.
-
Where is Jiksak Bioengineering headquartered?
Jiksak Bioengineering is headquartered in Kawasaki, Japan.
-
What is the size of Jiksak Bioengineering?
Jiksak Bioengineering has 10 total employees.
-
What industry is Jiksak Bioengineering in?
Jiksak Bioengineering’s primary industry is Drug Discovery.
-
Is Jiksak Bioengineering a private or public company?
Jiksak Bioengineering is a Private company.
-
What is Jiksak Bioengineering’s current revenue?
The current revenue for Jiksak Bioengineering is .
-
How much funding has Jiksak Bioengineering raised over time?
Jiksak Bioengineering has raised $7.63M.
-
Who are Jiksak Bioengineering’s investors?
CEJ Capital, Cyberdyne, SBI Investment, Zeon (Tokyo), and JAPAN CONVENTION SERVICES are 5 of 8 investors who have invested in Jiksak Bioengineering.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process